Live Webinar

Building a Cellular Therapy Program in the Community Oncology Setting: Perspectives and Lessons Learned

Presented by The Community Oncology Alliance

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
News|Videos|April 1, 2017

Dr Yehuda Handelsman on How Insulin Therapy Advances Can Boost Patients' Quality of Life

With new technologies that allow insulin to be delivered much more easily and at a targeted speed, diabetes treatment is less likely to interfere with patients’ lives, explained Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.

With new technologies that allow insulin to be delivered much more easily and at a targeted speed, diabetes treatment is less likely to interfere with patients’ lives, explained Yehuda Handelsman, MD, FACP, FACE, FNLA, medical director and principal investigator at the Metabolic Institute of America.

Related to this article

View more
Kenneth Komorny, PharmD, BCPS | Image: Moffitt Cancer Center
Tampa Experts Weigh the Economics of Bringing Bispecifics to Community Care
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Read more
Andrew D. Zelenetz, MD, PhD, is the chair of the NCCN B-cell Lymphomas panel. | Image: LinkedIn
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
Read more